Literature DB >> 19369101

Early control of seizures improves long-term outcome in children with tuberous sclerosis complex.

Roberta Bombardieri1, Mariangela Pinci, Romina Moavero, Caterina Cerminara, Paolo Curatolo.   

Abstract

Epilepsy associated with tuberous sclerosis complex (TSC) is characterized by early onset and intractable seizures in the majority of children. There is a solid evidence of clinical efficacy of vigabatrin in interrupting infantile spasms associated with TSC. Due to an early diagnosis we were able to start vigabatrin at the very early onset of seizures in 10 children, who subsequently underwent a long-term neurodevelopmental follow-up. At the final evaluation, a seizure free status was achieved in 50% of patients; 30% of individuals had a normal or borderline mental development, with no patients developing severe mental retardation and/or autism. Early control of seizures has a crucial role in preventing subsequent epileptic encephalopathy, and in reducing the cognitive/behavioural consequences of seizures, but does not guarantee for a normal mental outcome in children with TSC. 2009 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19369101     DOI: 10.1016/j.ejpn.2009.03.003

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  55 in total

Review 1.  Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

Authors:  Romina Moavero; Caterina Cerminara; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2010-04-01       Impact factor: 1.475

Review 2.  Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES).

Authors:  Carlos A Pardo; Rima Nabbout; Aristea S Galanopoulou
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 3.  The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.

Authors:  Paolo Curatolo; Marit Bjørnvold; Patricia E Dill; José Carlos Ferreira; Martha Feucht; Christoph Hertzberg; Anna Jansen; Sergiusz Jóźwiak; J Christopher Kingswood; Katarzyna Kotulska; Alfons Macaya; Romina Moavero; Rima Nabbout; Bernard A Zonnenberg
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

4.  The role of GABAergic system in neurodevelopmental disorders: a focus on autism and epilepsy.

Authors:  Paola Sgadò; Mark Dunleavy; Sacha Genovesi; Giovanni Provenzano; Yuri Bozzi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-09

5.  Predictors of Drug-Resistant Epilepsy in Tuberous Sclerosis Complex.

Authors:  Anna Jeong; Jo Anne Nakagawa; Michael Wong
Journal:  J Child Neurol       Date:  2017-12       Impact factor: 1.987

Review 6.  Epilepsy and Autism.

Authors:  Ashura W Buckley; Gregory L Holmes
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

7.  Early developmental trajectories associated with ASD in infants with tuberous sclerosis complex.

Authors:  Shafali Spurling Jeste; Joyce Y Wu; Damla Senturk; Kandice Varcin; Jordan Ko; Brigid McCarthy; Christina Shimizu; Kira Dies; Vanessa Vogel-Farley; Mustafa Sahin; Charles A Nelson
Journal:  Neurology       Date:  2014-06-11       Impact factor: 9.910

Review 8.  Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex.

Authors:  Emma van der Poest Clement; Floor E Jansen; Kees P J Braun; Jurriaan M Peters
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

9.  Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions.

Authors:  Jurriaan M Peters; Maxime Taquet; Anna K Prohl; Benoit Scherrer; Agnies M van Eeghen; Sanjay P Prabhu; Mustafa Sahin; Simon K Warfield
Journal:  Future Neurol       Date:  2013-09

10.  Clinical outcomes in bilateral Sturge-Weber syndrome.

Authors:  Bálint Alkonyi; Harry T Chugani; Samir Karia; Michael E Behen; Csaba Juhász
Journal:  Pediatr Neurol       Date:  2011-06       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.